Method for killing bacteria with an engineered postbiotic
The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin for use as a medicament, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the therapeutic treatment.
1. A method for killing bacteria infecting a subject in need thereof, comprising administering, to said subject in need thereof, a therapeutically effective amount of an engineered postbiotic composition comprising a microbial lysate and lysostaphin,
wherein said lysostaphin is obtained from bacteria heterologously expressing said lysostaphin,
wherein said microbial lysate and said lysostaphin have a synergistic effect in killing bacteria infecting said subject in need thereof.
2. The method according to claim 1 , wherein said bacteria heterologously expressing said lysostaphin are GRAS and/or probiotic bacteria.
3. The method according to claim 1 , wherein said bacteria heterologously expressing said lysostaphin have been genetically modified to express said lysostaphin.
4. The method according to claim 1 , wherein said bacteria heterologously expressing said lysostaphin are Lactobacillus or Escherichia bacteria.
5. The method according to claim 4 , wherein said bacteria heterologously expressing said lysostaphin are selected from the group consisting of Lactobacillus rhamnosus, Lactobacillus plantarum and Escherichia coli bacteria.
6. The method according to claim 5 , wherein said bacteria heterologously expressing said lysostaphin are Lactobacillus rhamnosus bacteria.
7. The method according to claim 1 , wherein said bacteria heterologously expressing said lysostaphin do not comprise any antibiotic resistance marker.
8. The method according to claim 1 , wherein said postbiotic composition further comprises at least two different bacteriocins and/or endolysins.
9. The method according to claim 8 , wherein said at least two different bacteriocins and/or endolysins target the same bacterial species.
10. The method according to claim 8 , wherein said at least two different bacteriocins and/or endolysins target different bacterial species.
11. The method according to claim 1 , wherein said engineered postbiotic stimulates growth of commensal bacterial species of the subject, and wherein said lysostaphin targets at least one unfavorable and/or pathogenic bacterial species.
12. The method according to claim 1 further for treating an inflammatory disorder in a subject in need thereof, wherein said postbiotic reduces inflammation.
13. The method according to claim 12 , wherein said postbiotic composition both has an anti-inflammatory effect on said subject and targets pro-inflammatory bacterial species of said subject.
14. The method according to claim 1 , for treating folliculitis in a subject in need thereof, wherein said postbiotic is applied to hair follicles.
15. The method according to claim 1 , wherein said lysostaphin targets Staphylococcus aureus , and wherein said postbiotic composition further stimulates growth of S. epidermidis.
16. The method according to claim 1 further for treating acne in a subject in need thereof, wherein said postbiotic is applied to skin of an acne patient.
17. The method according to claim 16 , wherein said postbiotic composition further comprises a combination of bacteriocins and/or endolysins targeting Staphylococcus aureus, Cutibacterium acnes and another bacteria of the Corynebacterium genera.
18. The method according to claim 1 further for treating atopic dermatitis in a subject in need thereof, wherein said postbiotic is applied to skin.
19. The method according to claim 18 , wherein said postbiotic kills Staphylococcus aureus infecting said subject.
20. The method according to claim 1 , wherein said postbiotic composition is administered topically, and said postbiotic composition is in the form of a pharmaceutical formulation for topical application.